Compare DTCK & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCK | VIVS |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.1M |
| IPO Year | 2023 | N/A |
| Metric | DTCK | VIVS |
|---|---|---|
| Price | $0.29 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 36.4K |
| Earning Date | 12-23-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,529,000.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.43 | ★ 35.92 |
| 52 Week Low | $0.23 | $1.41 |
| 52 Week High | $6.89 | $21.96 |
| Indicator | DTCK | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 44.41 |
| Support Level | $0.30 | $1.98 |
| Resistance Level | $0.33 | $2.18 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 3.33 | 14.29 |
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore, which specializes in the trading of three main categories of agricultural commodities, namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa, and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage, and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil, and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.